Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0000950170-25-069199
Filing Date
2025-05-12
Accepted
2025-05-12 16:10:05
Documents
3

Document Format Files

Seq Description Document Type Size
1 DEFA14A ikt-proxy-2025_defa14a.htm DEFA14A 10983
2 GRAPHIC img20386302_0.jpg GRAPHIC 3050111
3 GRAPHIC img20386302_1.jpg GRAPHIC 2026460
  Complete submission text file 0000950170-25-069199.txt   6997577
Mailing Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339
Business Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339 678-392-3419
Inhibikase Therapeutics, Inc. (Filer) CIK: 0001750149 (see all company filings)

EIN.: 263407249 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-39676 | Film No.: 25934872
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)